The current diagnostic modality used in high‐risk individuals is AFP plus ultrasound, which only distinguished 63% of early‐stage HCCs at a specificity of ≈84% reported in a recent meta‐analysis.[3] In clinical validation, the COMET‐LR achieved high sensitivities of 82.4% and 95.7% in stage I and II cancer cases, respectively, at a high specificity of 97.4%. The gene discussed is AFP; the disease is cancer.